INCYTE CORP
For the period ended Mar 31, 2024. Filed Apr 30, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed Apr 30, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
(c) During the three months ended March 31, 2024, the following officers (as defined in Rule 16a-1(f) under the Securities Exchange Act of 1934) of our Company adopted a prearranged trading plan relating to our common stock and intended to satisfy the affirmative defense of Rule 10b5–1(c) under the Securities Exchange Act of 1934:
Steven Stein, our Executive Vice President and Chief Medical Officer, adopted a trading plan on February 20, 2024 providing for the sale of up to an aggregate of 20,147 shares of our common stock until December 31, 2024.
Barry Flannelly, our Executive Vice President and General Manager, North America, adopted a trading plan on February 20, 2024 providing for the sale of up to an aggregate of 52,931 shares of our common stock until December 31, 2024.
Thomas Tray, our Vice President, Chief Accounting Officer, adopted a trading plan on March 7, 2024 providing for the sale of up to an aggregate of 1,093 shares of our common stock until June 28, 2024.
During the three months ended March 31, 2024, no director or officer (as defined in Rule 16a-1(f) under the Securities Exchange Act of 1934) of our Company adopted orterminated any contract, instruction or written plan for the purchase or sale of our securities, whether or not intended to satisfy the affirmative defense conditions of Rule 10b5-1(c), other than as set forth above.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.